Pharma's Market
SPECIAL REPORT
MOST SHARED
- Spain to Inject 19 Billion Euros into Bankia
- Fresh Fears as EU Finalises Reform Plans
- Beijing Faces Brussels Action on Telecoms Aid
- Citigroup Lost $20 Million on Facebook IPO Trades
- Zero China Growth Is ‘Probable’: Gordon Chang
- China Growth Risks Signal Need for Fiscal Action
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Marc Faber: 100% Chance of Global Recession
- GM Discloses $600,000 Contract With Ad Agency Tied to CFO's Wife
- Senate Summons Dimon to 'Get to the Bottom' of JPM Mess
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
- Citigroup Lost $20 Million on Facebook IPO Trades
- JPMorgan to Shake Up Risk Team After Big Loss: Report
- EU Finalizes Bank Reforms; Shifts Burden to Bondholders
- Spain to Inject Emergency 19 Billion Euros into Bankia
- EU Set to Launch Action Against China Over Telecom Aid
- JPMorgan to Shake Up Risk Team After Big Loss: Report
- Marc Faber: Chance of Global Recession Is Now 100%
- Cool Jobs: From Gold Stacker to Bed Tester
- 'Flash Sale' Sites: Gimmick, or Online Shopping Future?
RSS FEED
Pfizer's Stock Gets A Not So Happy Birthday From Viagra
Text Size 
Reporter
 |
CNBC.com |
] and, perhaps, some men and women are celebrating the tenth birthday of Viagra. So, happy birthday little blue pill. But I don't think the folks at Pfizer are popping the champagne corks. Today our stock whiz, Robert Hum, informs me that PFE closed at its lowest level since before the Food and Drug Administration approved Viagra.
The previous nearest closing low occured on October 1st, 1997. Since the world's biggest drug company held its analyst meeting earlier this month, the shares have fallen from $22-and-change to $20-and-change. As Jim Cramer pointed out this morning, though, the high dividend yield might make the stock attractive at this level.
Part of the problem is Pfizer's drug development pipeline. For example, it will not be a headliner at the American College of Cardiology meeting where I'm off to tomorrow. And this year's ACC is not all about Merck [MRK
Loading...
()
] and Schering-Plough's [SGP
Loading...
()
] Vytorin.
Tomorrow Lilly [LLY
Loading...
()
] releases data on whether its bloodthinner, which is on a fast track for possible FDA approval, did a better job than Plavix (Bristol-Myers Squibb and Sanofi-Aventis) at preventing blood clots from forming in stent patients. And then on Monday morning, look for results coming out Monday morning on a weightloss and cholesterol drug from Merck.
See you bright and early on "Squawk Box" at 6 a.m. ET live from McCormick Place.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
